Skip to main content
Top
Published in: BMC Medicine 1/2021

01-12-2021 | SARS-CoV-2 | Correspondence

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

Authors: Carlota Dobaño, Anna Ramírez-Morros, Selena Alonso, Josep Vidal-Alaball, Gemma Ruiz-Olalla, Marta Vidal, Rocío Rubio, Emma Cascant, Daniel Parras, Natalia Rodrigo Melero, Pau Serra, Carlo Carolis, Pere Santamaria, Anna Forcada, Jacobo Mendioroz, Ruth Aguilar, Gemma Moncunill, Anna Ruiz-Comellas

Published in: BMC Medicine | Issue 1/2021

Login to get access

Abstract

We assessed the duration and baseline determinants of antibody responses to SARS-CoV-2 spike antigens and the occurrence of reinfections in a prospective cohort of 173 Spanish primary health care worker patients followed initially for 9 months and subsequently up to 12.5 months after COVID-19 symptoms onset. Seropositivity to SARS-CoV-2 spike and receptor-binding domain antigens up to 149–270 days was 92.49% (90.17% IgG, 76.3% IgA, 60.69% IgM). In a subset of 64 health care workers who had not yet been vaccinated by April 2021, seropositivity was 96.88% (95.31% IgG, 82.81% IgA) up to 322–379 days post symptoms onset. Four suspected reinfections were detected by passive case detection, two among seronegative individuals (5 and 7 months after the first episode), and one low antibody responder. Antibody levels significantly correlated with fever, hospitalization, anosmia/hypogeusia, allergies, smoking, and occupation. Stable sustainment of IgG responses raises hope for long-lasting COVID-19 vaccine immunity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (80- ). 2020;370:1227–30.CrossRef Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (80- ). 2020;370:1227–30.CrossRef
2.
go back to reference Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, et al. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Med. 2021;2:100228.CrossRef Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, et al. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Med. 2021;2:100228.CrossRef
3.
go back to reference Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201–1213.e14.CrossRef Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201–1213.e14.CrossRef
4.
go back to reference Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med. 2021;2:281–295.e4.CrossRef Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med. 2021;2:281–295.e4.CrossRef
5.
go back to reference Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre- existing antibodies to seasonal human coronaviruses on COVID-19. medRxiv. 2021:2021.02.22.21252150 2021.02.22.21252150v2. Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre- existing antibodies to seasonal human coronaviruses on COVID-19. medRxiv. 2021:2021.02.22.21252150 2021.02.22.21252150v2.
7.
go back to reference Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, Jurczyszak D, Bermudez-Gonzalez M, Nádas A, Liu S, Lee B, Zolla-Pazner S, Hioe CE. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2021;223(6):957–70. https://doi.org/10.1093/infdis/jiaa784. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, Jurczyszak D, Bermudez-Gonzalez M, Nádas A, Liu S, Lee B, Zolla-Pazner S, Hioe CE. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2021;223(6):957–70. https://​doi.​org/​10.​1093/​infdis/​jiaa784.
9.
go back to reference Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. Science (80- ). 2021;371:eabf4063.CrossRef Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. Science (80- ). 2021;371:eabf4063.CrossRef
12.
go back to reference Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53:925–933.e4.CrossRef Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53:925–933.e4.CrossRef
14.
go back to reference Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2020:2020.11.03.367391. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2020:2020.11.03.367391.
15.
go back to reference Pradenas E, Trinité B, Urrea V, Marfil S, Ávila-Nieto C, Rodríguez de la Concepción ML, Tarrés-Freixas F, Pérez-Yanes S, Rovirosa C, Ainsua-Enrich E, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Paredes R, Mateu L, Chamorro A, Massanella M, Carrillo J, Clotet B, Blanco. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. J. Med (N Y). 2021;2(3):313–20.e4. https://doi.org/10.1016/j.medj.2021.01.005. Epub 2021 Jan 31. Pradenas E, Trinité B, Urrea V, Marfil S, Ávila-Nieto C, Rodríguez de la Concepción ML, Tarrés-Freixas F, Pérez-Yanes S, Rovirosa C, Ainsua-Enrich E, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Paredes R, Mateu L, Chamorro A, Massanella M, Carrillo J, Clotet B, Blanco. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. J. Med (N Y). 2021;2(3):313–20.e4. https://​doi.​org/​10.​1016/​j.​medj.​2021.​01.​005. Epub 2021 Jan 31.
17.
go back to reference Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens. J Clin Microbiol. 2020;59:e01731–20. Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens. J Clin Microbiol. 2020;59:e01731–20.
21.
22.
go back to reference Jonsdottir HR, Bielecki M, Siegrist D, Buehrer TW, Züst R, Deuel JW. Titers of neutralizing antibodies against SARS-CoV-2 are independent of symptoms of non-severe COVID-19 in young adults. Viruses. 2021;13. https://doi.org/10.3390/v13020284. Jonsdottir HR, Bielecki M, Siegrist D, Buehrer TW, Züst R, Deuel JW. Titers of neutralizing antibodies against SARS-CoV-2 are independent of symptoms of non-severe COVID-19 in young adults. Viruses. 2021;13. https://​doi.​org/​10.​3390/​v13020284.
23.
Metadata
Title
Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19
Authors
Carlota Dobaño
Anna Ramírez-Morros
Selena Alonso
Josep Vidal-Alaball
Gemma Ruiz-Olalla
Marta Vidal
Rocío Rubio
Emma Cascant
Daniel Parras
Natalia Rodrigo Melero
Pau Serra
Carlo Carolis
Pere Santamaria
Anna Forcada
Jacobo Mendioroz
Ruth Aguilar
Gemma Moncunill
Anna Ruiz-Comellas
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-021-02032-2

Other articles of this Issue 1/2021

BMC Medicine 1/2021 Go to the issue